Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Emory University
Merck Sharp & Dohme LLC
Eli Lilly and Company
Fudan University
Royal Marsden NHS Foundation Trust
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Exelixis
Shanghai Junshi Bioscience Co., Ltd.
Wake Forest University Health Sciences
Mersana Therapeutics
Cellectar Biosciences, Inc.
Stanford University
Bristol-Myers Squibb
AbbVie
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Beijing Biotech
Yonsei University
Novartis
Fudan University
Exscientia AI Limited
Genmab
University of Washington
Royal Marsden NHS Foundation Trust
Epsilogen Ltd
Beijing Biotech
The Methodist Hospital Research Institute
Swiss Cancer Institute
Zumutor Biologics Inc.
Cedars-Sinai Medical Center
H. Lee Moffitt Cancer Center and Research Institute
Universitaire Ziekenhuizen KU Leuven
H. Lee Moffitt Cancer Center and Research Institute
Sun Yat-sen University
Bristol-Myers Squibb
IDEAYA Biosciences
SillaJen, Inc.
University of Iowa
Radiopharm Theranostics, Ltd
Fudan University
Eli Lilly and Company